These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9679976)

  • 1. Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC.
    Schoenberger SP; Jonges LE; Mooijaart RJ; Hartgers F; Toes RE; Kast WM; Melief CJ; Offringa R
    Cancer Res; 1998 Jul; 58(14):3094-100. PubMed ID: 9679976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
    Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
    Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
    Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
    Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased generation of anti-tumor immunity after intrasplenic immunization.
    Cayeux S; Qin Z; Dörken B; Blankenstein T
    Eur J Immunol; 2001 May; 31(5):1392-9. PubMed ID: 11465096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTL induction by cross-priming is restricted to immunodominant epitopes.
    Pavelic V; Matter MS; Mumprecht S; Breyer I; Ochsenbein AF
    Eur J Immunol; 2009 Mar; 39(3):704-16. PubMed ID: 19189311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
    Chung SW; Cohen EP; Kim TS
    Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy.
    Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE
    Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice.
    Kim TS; Lee BC; Kim E; Cho D; Cohen EP
    Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells.
    Guilloux Y; Bai XF; Liu X; Zheng P; Liu Y
    Cancer Res; 2001 Feb; 61(3):1107-12. PubMed ID: 11221840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo.
    Constant S; Schweitzer N; West J; Ranney P; Bottomly K
    J Immunol; 1995 Oct; 155(8):3734-41. PubMed ID: 7561077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
    Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
    Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
    Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
    Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells.
    Maric M; Zheng P; Sarma S; Guo Y; Liu Y
    Cancer Res; 1998 Aug; 58(15):3376-84. PubMed ID: 9699669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
    Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
    J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.